BrightSpring Health Services

Overview

BrightSpring Health Services is a diversified pharmacy and healthcare services company that operates across multiple modalities: specialty pharmacy, home infusion, long-term care (LTC) pharmacy, and home health/hospice. The company was formed through the 2019 merger of BrightSpring (disability and behavioral health services) and PharMerica (LTC pharmacy), subsequently built out through aggressive M&A under KKR ownership, and IPO’d on NASDAQ in January 2024. (Source: raw/research/brightspring-health-services.pplx.md)

In FY2025, BrightSpring generated $12.9B in revenue (+28% year-over-year) and $618M in adjusted EBITDA (+34%). The company’s pharmacy services segment — anchored by Onco360 (oncology SP), CareMed (rare/orphan disease SP), and Amerita (home infusion) — drives the growth story, while PharMerica (LTC pharmacy, 180+ sites, 350K daily patients) provides stable, recurring revenue.

BrightSpring’s unique value proposition is the integrated platform: a single company can handle specialty dispensing, home infusion, LTC pharmacy, and home health — enabling cross-selling and dual-channel strategies like the Leqembi model (CareMed dispensing + Amerita infusion).

Services & Capabilities

Onco360 — Oncology Specialty Pharmacy

BrightSpring’s flagship specialty pharmacy brand, and the #1 independent oncology SP:

• 149+ limited distribution drug (LDD) designations
• 275 field-based specialty representatives
• 100 NPS (net promoter score)
• 4-day average time-to-first-fill
• Deep oncology formulary covering oral oncolytics, supportive care, and emerging IO therapies

CareMed — Rare/Orphan Disease Specialty Pharmacy

• Focused on rare and orphan disease therapies
• 100 NPS — three consecutive perfect-score quarters
• Complementary to Onco360’s oncology focus
• Handles Leqembi dispensing in dual-channel model with Amerita

Amerita — Home Infusion

• National home infusion services
• ~6% of the $22B U.S. home infusion market
• 94% NPS
• Infusion suite and in-home capabilities
• Key competitor to Option Care Health (the market leader at ~20% share)
• Administers Leqembi infusions in dual-channel model with CareMed

PharMerica — LTC Pharmacy

• Long-term care pharmacy serving skilled nursing facilities, assisted living, and behavioral health
• 180+ pharmacy sites
• 350,000 daily patients
• Stable, recurring revenue base
• Benefits from aging demographics and institutional pharmacy demand

Home Health & Hospice

• Expanded via Q4 2025 Amedisys/LHC Group acquisition (107 branches, $238M)
• Complements pharmacy services with clinical home care
• Enables integrated care models spanning medication management + clinical services

Leqembi Dual-Channel Model

A distinctive BrightSpring innovation:

• CareMed: Dispenses Leqembi (lecanemab for Alzheimer’s)
• Amerita: Administers the infusion in-home or at infusion suites
• Single-company coordination reduces handoffs and improves patient experience
• Template for future dual-channel therapies (biosimilar infusions, gene therapy support)

Competitive Position

BrightSpring’s competitive positioning is defined by breadth and integration:

• #4 specialty pharmacy nationally: Behind CVS Specialty, Accredo/Evernorth, and Optum Specialty — but the largest independent (non-PBM-owned) SP by revenue.
• #1 independent oncology SP: Onco360’s 149+ LDDs and field force are unmatched among independent specialty pharmacies in oncology.
• Multi-modal integration: No other company offers SP + home infusion + LTC pharmacy + home health at BrightSpring’s scale. Option Care Health is larger in home infusion but lacks SP scale; PBM-owned SPs lack home health/LTC.
• KKR transition: KKR’s 21.8% stake is being divested post-IPO. Full public float will remove the PE overhang and potentially attract broader institutional ownership.

Key competitors by segment: Option Care Health (home infusion), PANTHERx Rare and Orsini (rare disease SP), Accredo/Evernorth and PBM-owned SPs (overall SP scale), Omnicare/CVS (LTC pharmacy).

Recent Developments

• Q4 2025: Acquired 107 Amedisys/LHC Group home health branches for $238M, significantly expanding the home health footprint.
• March 2026: Divested Community Living segment for $835M — a strategic deleveraging move, shedding the legacy disability/behavioral health services to focus on the pharmacy and healthcare services platform.
• FY2025 results: $12.9B revenue (+28%), $618M adjusted EBITDA (+34%). Strong organic growth plus M&A contributions.
• 2026 guidance: $14.45-15.0B revenue; $760-790M adjusted EBITDA.
• Deleveraging: Net leverage improved from 4.16x to 2.99x; Community Living divestiture provides ~$2B in M&A firepower.
• Stock performance: Up 219% from IPO price of $13 to approximately $43-46 per share.
• January 2024: IPO on NASDAQ (BTSG) at $13/share.

Client & Partner Ecosystem

Manufacturer Relationships

• 149+ LDD designations across oncology, rare disease, and specialty therapeutics
• Deep field force (275 specialty reps) maintaining prescriber and manufacturer relationships
• Leqembi (Eisai/Biogen) dual-channel partnership is a flagship reference case

Payer Relationships

National payer contracts spanning commercial, Medicare, and Medicaid across all pharmacy modalities (SP, infusion, LTC).

Health System Relationships

• LTC pharmacy (PharMerica) serves skilled nursing and institutional partners
• Home health referral networks expanded via Amedisys/LHC acquisition
• Infusion referral pathways from hospital discharge planning

PE/Investor

• KKR: 21.8% ownership (divesting post-IPO). KKR was the original sponsor of PharMerica and architect of the BrightSpring merger/build-out strategy.

Technology Platform

• Onco360 clinical platform: Oncology-specific dispensing, clinical monitoring, REMS management, and outcomes tracking
• CareMed rare disease platform: Patient journey tracking, hub-like services integrated with dispensing
• Amerita infusion management: Scheduling, nursing coordination, clinical documentation for home infusion
• PharMerica LTC systems: Institutional pharmacy management, medication pass tracking, regulatory compliance
• Cross-platform analytics: Emerging capability to leverage data across modalities for integrated care insights

Therapeutic Focus

BrightSpring’s therapeutic focus varies by brand:

• Oncology (Onco360): Oral oncolytics, immunotherapy support, supportive care — the deepest oncology SP formulary among independents
• Rare/orphan disease (CareMed): Growing rare disease portfolio with 100 NPS
• Neurology (Amerita + CareMed): Leqembi dual-channel model; MS and neuromuscular infusions
• Infectious disease (Amerita): IV antibiotics and antifungals
• Immunology (Amerita): IG therapy, autoimmune infusions
• LTC therapeutics (PharMerica): Broad formulary serving aging/institutional populations
• Behavioral health: Legacy from BrightSpring origins (partially divested via Community Living sale)

Sources

• BrightSpring Health Services research